CorMedix to Participate in Needham Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy CRMD?
Source: Newsfilter
- Management Participation: CorMedix Therapeutics' senior management will engage in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, aiming to enhance investor interaction and boost company visibility.
- Product Line Expansion: The company is commercializing DefenCath® for preventing catheter-related bloodstream infections in adult patients undergoing hemodialysis, while also promoting a portfolio of anti-infective products, including MINOCIN® and REZZAYO®, to meet market demand.
- Clinical Research Progress: CorMedix is conducting clinical studies for DefenCath in Total Parenteral Nutrition and pediatric dialysis populations, indicating the company's potential for expansion into new areas, which is expected to support future product line growth.
- REZZAYO Study Results: REZZAYO is currently approved for treating candidemia and invasive candidiasis in adults, with topline results from its prophylactic study for adult patients undergoing allogeneic BMT expected in Q2 2026, potentially driving an increase in the company's stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRMD
Wall Street analysts forecast CRMD stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.390
Low
13.00
Averages
13.67
High
15.00
Current: 7.390
Low
13.00
Averages
13.67
High
15.00
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CorMedix to Participate in Needham Conference
- Management Participation: CorMedix Therapeutics' senior management will engage in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, aiming to enhance investor interaction and boost company visibility.
- Product Line Expansion: The company is commercializing DefenCath® for preventing catheter-related bloodstream infections in adult patients undergoing hemodialysis, while also promoting a portfolio of anti-infective products, including MINOCIN® and REZZAYO®, to meet market demand.
- Clinical Research Progress: CorMedix is conducting clinical studies for DefenCath in Total Parenteral Nutrition and pediatric dialysis populations, indicating the company's potential for expansion into new areas, which is expected to support future product line growth.
- REZZAYO Study Results: REZZAYO is currently approved for treating candidemia and invasive candidiasis in adults, with topline results from its prophylactic study for adult patients undergoing allogeneic BMT expected in Q2 2026, potentially driving an increase in the company's stock price.
See More
CorMedix Reports 2025 Financial Results and Guidance
- Significant Revenue Growth: CorMedix reported a net income of $14.02 million in Q4 2025, translating to $0.16 per share, a slight decrease from $13.46 million and $0.20 per share last year, while total revenue surged from $31.21 million to $128.62 million, indicating strong market performance.
- Annual Performance Reversal: For the full year 2025, the company achieved a net income of $163.06 million, or $2.04 per diluted share, a stark contrast to the previous year's net loss of $17.93 million and a loss per share of $0.30, showcasing a successful turnaround in financial health.
- Positive Future Outlook: CorMedix reiterated its 2026 net revenue guidance of $300 to $320 million, with adjusted EBITDA expected between $100 and $125 million, reflecting the company's confidence in future growth and market potential.
- Pipeline and Clinical Progress: The company is conducting clinical studies for DefenCath and plans to develop it for other patient populations, while also commercializing Melinta Therapeutics' anti-infective products, thereby enriching its product portfolio and enhancing market competitiveness.
See More
CorMedix Q4 2025 Earnings Call Insights
- Strong Sales Performance: CorMedix reported net revenue of $128.6 million in Q4 2025, with DefenCath contributing $91.2 million and the Melinta portfolio adding $37.4 million, indicating sustained growth across its commercial portfolio and laying a solid foundation for future market expansion.
- Acquisition Integration Progress: The successful acquisition of Melinta Therapeutics in Q3 led to $35 million in synergies achieved in Q4, demonstrating management's efficient execution in integrating new assets, which is expected to enhance overall profitability.
- Optimistic Future Outlook: Management reaffirmed guidance for 2026 DefenCath revenue of $150 million to $170 million and $100 million to $125 million for 2027, reflecting confidence in future revenue growth while emphasizing strategic planning around price adjustments and customer retention.
- Significant R&D Progress: The global Phase III study for REZZAYO was completed in September, with top-line data expected in Q2 2026, and a potential market opportunity estimated at $2.5 billion, highlighting the company's strong market potential in the antifungal product space.
See More
CorMedix Q4 2025 Earnings Misses Expectations
- Disappointing Earnings Report: CorMedix reported Q4 2025 earnings per share of $0.16, missing market expectations by $0.66, resulting in a ~12% drop in stock price to the lowest level in nearly 11 months, indicating significant challenges in profitability.
- Tax Expense Impact: The company recorded $42.4 million in tax expenses for Q4, leading to a ~20% year-over-year decline, which negatively affected overall financial performance and highlighted the burden of tax liabilities on earnings.
- Significant Revenue Growth: Despite challenges, CorMedix's operating income surged over 350% year-over-year to $59.1 million, with total revenue witnessing a more than fourfold increase to $128.6 million, exceeding market expectations by $1.6 million, showcasing strong product demand.
- Stable Future Outlook: The company reaffirmed its revenue guidance for 2026, projecting between $300 million and $320 million, compared to analysts' forecast of $308.96 million, reflecting management's confidence in future growth.
See More
CorMedix Reports Q4 Revenue Surge Amid Mixed Earnings
- Significant Revenue Growth: CorMedix reported Q4 revenue of $128.6 million, a remarkable 312% year-on-year increase, driven by $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio, indicating initial success from the acquisition integration.
- Sharp Rise in Expenses: Total operating expenses surged to $48.2 million in Q4, up 181% year-on-year, primarily due to $4.1 million in one-time costs related to the Melinta acquisition, reflecting financial pressures during the expansion and integration phases.
- Strong Cash Position: CorMedix ended 2025 with $148.5 million in cash and short-term investments, maintaining robust liquidity despite high expenditures, which provides a solid foundation for future growth initiatives.
- Market Reaction Volatility: Despite exceeding revenue expectations, CorMedix's stock fell over 11% post-earnings release due to concerns over EPS falling short of estimates, yet retail sentiment on social media shifted to bullish, indicating investor optimism about future performance.
See More
CORMEDIX Q4 OPERATING EXPENSES REVISED TO USD 48.182 MILLION
- Operating Expenses: Cormedix reported its Q4 operating expenses amounting to USD 48.182 million.
- Correction Notice: The reported amount has been corrected to reflect accurate financial data.
See More
CorMedix to Participate in Needham Conference
- Management Participation: CorMedix Therapeutics' senior management will engage in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, aiming to enhance investor interaction and boost company visibility.
- Product Line Expansion: The company is commercializing DefenCath® for preventing catheter-related bloodstream infections in adult patients undergoing hemodialysis, while also promoting a portfolio of anti-infective products, including MINOCIN® and REZZAYO®, to meet market demand.
- Clinical Research Progress: CorMedix is conducting clinical studies for DefenCath in Total Parenteral Nutrition and pediatric dialysis populations, indicating the company's potential for expansion into new areas, which is expected to support future product line growth.
- REZZAYO Study Results: REZZAYO is currently approved for treating candidemia and invasive candidiasis in adults, with topline results from its prophylactic study for adult patients undergoing allogeneic BMT expected in Q2 2026, potentially driving an increase in the company's stock price.
See More
CorMedix Reports 2025 Financial Results and Guidance
- Significant Revenue Growth: CorMedix reported a net income of $14.02 million in Q4 2025, translating to $0.16 per share, a slight decrease from $13.46 million and $0.20 per share last year, while total revenue surged from $31.21 million to $128.62 million, indicating strong market performance.
- Annual Performance Reversal: For the full year 2025, the company achieved a net income of $163.06 million, or $2.04 per diluted share, a stark contrast to the previous year's net loss of $17.93 million and a loss per share of $0.30, showcasing a successful turnaround in financial health.
- Positive Future Outlook: CorMedix reiterated its 2026 net revenue guidance of $300 to $320 million, with adjusted EBITDA expected between $100 and $125 million, reflecting the company's confidence in future growth and market potential.
- Pipeline and Clinical Progress: The company is conducting clinical studies for DefenCath and plans to develop it for other patient populations, while also commercializing Melinta Therapeutics' anti-infective products, thereby enriching its product portfolio and enhancing market competitiveness.
See More
CorMedix Q4 2025 Earnings Call Insights
- Strong Sales Performance: CorMedix reported net revenue of $128.6 million in Q4 2025, with DefenCath contributing $91.2 million and the Melinta portfolio adding $37.4 million, indicating sustained growth across its commercial portfolio and laying a solid foundation for future market expansion.
- Acquisition Integration Progress: The successful acquisition of Melinta Therapeutics in Q3 led to $35 million in synergies achieved in Q4, demonstrating management's efficient execution in integrating new assets, which is expected to enhance overall profitability.
- Optimistic Future Outlook: Management reaffirmed guidance for 2026 DefenCath revenue of $150 million to $170 million and $100 million to $125 million for 2027, reflecting confidence in future revenue growth while emphasizing strategic planning around price adjustments and customer retention.
- Significant R&D Progress: The global Phase III study for REZZAYO was completed in September, with top-line data expected in Q2 2026, and a potential market opportunity estimated at $2.5 billion, highlighting the company's strong market potential in the antifungal product space.
See More
CorMedix Q4 2025 Earnings Misses Expectations
- Disappointing Earnings Report: CorMedix reported Q4 2025 earnings per share of $0.16, missing market expectations by $0.66, resulting in a ~12% drop in stock price to the lowest level in nearly 11 months, indicating significant challenges in profitability.
- Tax Expense Impact: The company recorded $42.4 million in tax expenses for Q4, leading to a ~20% year-over-year decline, which negatively affected overall financial performance and highlighted the burden of tax liabilities on earnings.
- Significant Revenue Growth: Despite challenges, CorMedix's operating income surged over 350% year-over-year to $59.1 million, with total revenue witnessing a more than fourfold increase to $128.6 million, exceeding market expectations by $1.6 million, showcasing strong product demand.
- Stable Future Outlook: The company reaffirmed its revenue guidance for 2026, projecting between $300 million and $320 million, compared to analysts' forecast of $308.96 million, reflecting management's confidence in future growth.
See More
CorMedix Reports Q4 Revenue Surge Amid Mixed Earnings
- Significant Revenue Growth: CorMedix reported Q4 revenue of $128.6 million, a remarkable 312% year-on-year increase, driven by $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio, indicating initial success from the acquisition integration.
- Sharp Rise in Expenses: Total operating expenses surged to $48.2 million in Q4, up 181% year-on-year, primarily due to $4.1 million in one-time costs related to the Melinta acquisition, reflecting financial pressures during the expansion and integration phases.
- Strong Cash Position: CorMedix ended 2025 with $148.5 million in cash and short-term investments, maintaining robust liquidity despite high expenditures, which provides a solid foundation for future growth initiatives.
- Market Reaction Volatility: Despite exceeding revenue expectations, CorMedix's stock fell over 11% post-earnings release due to concerns over EPS falling short of estimates, yet retail sentiment on social media shifted to bullish, indicating investor optimism about future performance.
See More
CORMEDIX Q4 OPERATING EXPENSES REVISED TO USD 48.182 MILLION
- Operating Expenses: Cormedix reported its Q4 operating expenses amounting to USD 48.182 million.
- Correction Notice: The reported amount has been corrected to reflect accurate financial data.
See More
